| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
31,350,000 |
| Market
Cap: |
16.03(M) |
| Last
Volume: |
15,038 |
Avg
Vol: |
14,996 |
| 52
Week Range: |
$0.2009 - $0.648 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalyst Biosciences is a research and clinical development biopharmaceutical company. Co.'s complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, improved albumin-fused Complement Factor I (CFI) molecule intended for prophylactic subcutaneous or intravitreal administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential component 3 degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration. Co. has several engineered protease programs in discovery or early non-clinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
9,750 |
| Total Buy Value |
$0 |
$0 |
$0 |
$4,584 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
40,000 |
40,000 |
40,000 |
40,000 |
| Total Sell Value |
$668,200 |
$668,200 |
$668,200 |
$668,200 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
2 |
2 |
2 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Usman Nassim |
|
• • – |
2024-04-01 |
4 |
AS |
$16.15 |
$323,000 |
D/D |
(20,000) |
1,636 |
|
- |
|
| Usman Nassim |
|
• • – |
2024-04-01 |
4 |
OE |
$6.93 |
$138,600 |
D/D |
20,000 |
21,636 |
|
- |
|
| Usman Nassim |
|
• • – |
2024-03-15 |
4 |
AS |
$17.26 |
$345,200 |
D/D |
(20,000) |
1,636 |
|
- |
|
| Usman Nassim |
|
• • – |
2024-03-15 |
4 |
OE |
$6.93 |
$138,600 |
D/D |
20,000 |
21,636 |
|
- |
|
| Ma Songjiang |
President |
• • – |
2023-10-30 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
2,942,467 |
|
- |
|
| Luo Ying |
|
• • – |
2023-10-30 |
4 |
A |
$0.00 |
$0 |
I/I |
2,840,376 |
2,840,376 |
|
- |
|
| Gni Usa, Inc. |
|
• • • |
2023-10-30 |
4 |
A |
$0.00 |
$0 |
I/I |
63,588,119 |
64,005,887 |
|
- |
|
| Gni Usa, Inc. |
|
– – • |
2023-10-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,266,521 |
|
-3% |
|
| Gni Hong Kong Ltd |
|
• • • |
2023-10-27 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,371,304) |
0 |
|
- |
|
| Gni Hong Kong Ltd |
10% Owner |
– – • |
2022-12-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,266,521 |
|
-59% |
|
| Usman Nassim |
President & CEO |
• • – |
2022-08-09 |
4 |
B |
$0.47 |
$1,528 |
D/D |
3,250 |
24,541 |
2.73 |
-73% |
|
| Miller Seline E. |
SVP Finance; Interim CFO & PAO |
• – – |
2022-08-09 |
4 |
B |
$0.47 |
$1,528 |
D/D |
3,250 |
6,500 |
2.66 |
-73% |
|
| Blouse Grant E. |
Chief Scientific Officer |
• – – |
2022-08-09 |
4 |
B |
$0.47 |
$1,528 |
D/D |
3,250 |
9,417 |
2.66 |
-73% |
|
| Miller Seline E. |
SVP Finance; Interim CFO & PAO |
• – – |
2022-02-09 |
4 |
B |
$0.46 |
$1,495 |
D/D |
3,250 |
3,250 |
2.66 |
144% |
|
| Usman Nassim |
President & CEO |
• • – |
2022-02-09 |
4 |
B |
$0.46 |
$1,495 |
D/D |
3,250 |
21,291 |
2.73 |
144% |
|
| Blouse Grant E. |
Chief Scientific Officer |
• – – |
2022-02-09 |
4 |
B |
$0.46 |
$1,495 |
D/D |
3,250 |
6,167 |
2.66 |
144% |
|
| Hunt Andrea |
Director |
– • – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
7,521 |
28,228 |
|
- |
|
| Williams Eddie |
Director |
– • – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
12,308 |
34,804 |
|
- |
|
| Ling Geoffrey M.d. |
Director |
– • – |
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
12,855 |
31,790 |
|
- |
|
| Williams Eddie |
Director |
– • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,980 |
22,496 |
|
- |
|
| Hunt Andrea |
Director |
– • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,824 |
20,707 |
|
- |
|
| Ling Geoffrey M.d. |
Director |
– • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,858 |
18,935 |
|
- |
|
| Desouza Errol B |
Director |
– • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,588 |
29,801 |
|
- |
|
| Lawlor Augustine |
Director |
– • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,839 |
24,573 |
|
- |
|
| Levy Howard |
Chief Medical Officer |
• – – |
2021-08-09 |
4 |
B |
$3.62 |
$2,313 |
D/D |
639 |
639 |
2.66 |
-76% |
|
141 Records found
|
|
Page 1 of 6 |
|
|
